Dr. Miroslav Reljanović is a medical doctor and a board-certified neurologist.

Whilst practicing as a physician in a large WHO Collaborating Centre in Zagreb, Croatia, he was the clinical investigator in numerous Phase II and III studies in the field of neurology and a consultant to various pharmaceutical companies. Miro founded Ergomed in 1997 and introduced the novel Study Site Coordination model as an intrinsic part of the conduct of clinical studies.

Miro co-founded PrimeVigilance in 2008, that quickly became a leading specialist vendor of contracted pharmacovigilance services to the pharmaceutical industry, winning the Queen’s Award for enterprise in 2014 and again in 2019.

In July 2014 Miro led Ergomed through a successful IPO on the AIM market of the London Stock Exchange and the subsequent completion of numerous acquisitions and secondary offerings.

Miro brings to the Board his in-depth experience in clinical development and the operational execution of drug development, as well as a detailed knowledge of the Group and its operations.

Miro is Chair of Ergomed’s Nomination Committee.